IMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
(1)
NEW YORK, March 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ( HSAC , Immunovant , or the Company ) (NASDAQ: IMVT; HSACU; HSAC; and HSACW) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Immunovant securities between October 2, 2019 and February 1, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
/PRNewswire/ Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Immunovant, Inc (IMVT) forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Health
your username
February 22, 2021
A shareholder has sued Immunovant, Inc. and several of its officers after the company’s stock price tumbled earlier this month. The approximately 42% drop reportedly occurred after the clinical-stage biopharmaceutical company announced a “voluntary pause” of the trial of its myasthenia gravis and thyroid eye disease drug, known as IMVT-1401, in light of concerning side effects.
According to the Feb. 19 Eastern District of New York complaint, Immunovant develops “monoclonal antibodies for the treatment of autoimmune diseases.” In September 2019, the filing explains, Health Sciences Acquisitions Corporation (HSAC) proposed a special acquisition of Immunovant Sciences Ltd. (Legacy Immunovant). Legacy Immunovant subsequently became a wholly-owned subsidiary of HSAC, and when the deal closed, HSAC changed its name to “Immunovant, Inc,” now a defendant in this lawsuit.